Leukaemia (chronic lymphocytic, first line) - rituximab
Rituximab for first line treatment of chronic lymphocytic leukaemia
Summary
Rituximab is recommended as a possible first treatment for people with chronic lymphocytic leukaemia who are able to take fludarabine in combination with cyclophosphamide. Rituximab should only be used in combination with fludarabine and cyclophosphamide. Rituximab is not recommended in combinatio ...
Guidance documents
Implementing this guidance
Other information
We will consult on our review plans for this guidance in December 2010
About this guidance
Technology appraisals TA174
Issued: July 2009
How this guidance was produced